Employers are dropping GLP-1 weight-loss coverage Three 2026 surveys point the same way. A Business Group on Health survey found 60% of large employers now cover GLP-1s for weight loss, down from 72% in 2025, with Cigna and PwC already out and PepsiCo and Starbucks following in October. Employers Health says about 65% of its
THIS WEEK IN 30 SECONDS New analyses add evidence that tirzepatide can improve several cardiometabolic risk markers at the same time; a separate three-year analysis suggests sustained improvement in predicted cardiovascular risk; and dermatology investigators report a mix of improved inflammatory skin symptoms and more frequent cosmetic changes with larger weight loss. 1. Tirzepatide:
This week’s News Flash highlights five clinically useful publications appearing in the August literature. The emphasis is on treatment persistence, body composition, oral obesity medications, and practical decisions about treatment goals. 1. Why Do Patients Stop GLP-1 Medications? A New National Survey Adds Real-World Detail Evidence status: Peer-reviewed national survey A newly published U.S. survey
This week’s update highlights four clinically relevant studies that were not central topics in the prior Belite report. The findings involve early treatment response, medication persistence, reduced-frequency maintenance dosing, bone health, and cardiovascular outcomes. Several are observational or exploratory and should not be interpreted as definitive practice-changing evidence. Rapid Early Weight Loss Did Not Appear
